EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy

Mandour O Mandour iD, Anna Stears, Agatha Van Der Klaauw, Catherine Flanagan, Lisa Gaff, Charlotte Jenkins, David B Savage

The Journal of Clinical Endocrinology & Metabolism · 13.08.2026 · 111 (9) · e2146-e2153

DOI: 10.1210/clinem/dgag126 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 20.03.2026. Verfasst von Mandour O Mandour und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Cambridge CB2 0QQ, UK. Hauptthemen laut MEDLINE: Tirzepatide, Lipodystrophy, Familial Partial. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health Research, Wellcome Trust, NIHR Rare Disease Translational Research Collaboration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lipodystrophy syndromes (LD) are a group of rare conditions characterized by the generalized or partial absence and/or dysfunction of adipocytes. Due to the lack of fat storage capacity, excess lipid accumulates in other tissues, leading to severe insulin resistance. At present, effective therapeutic options remain limited, with metreleptin currently the only specific licensed treatment. To this end, we evaluated the therapeutic impact of tirzepatide in people with partial lipodystrophy (PLD).

Methods

This was a single-center, retrospective, observational study, including all patients with PLD treated with tirzepatide between January 2022 and September 2025.

Results

Forty patients with PLD were included FPLD1 like = 26 (65%), FPLD2 = 4 (10%), FPLD3 = 7 (17.5%), FPLD7 = 1 (2.5%), APLD = 1 (2.5%), unclassified = 1 (2.5%). 87.5% (n = 35) were female with a median age of 47 years (IQR 39—59) and a median BMI of 31.5 kg/m2 (IQR 27.3 to 35.5). After a median 9.5 month follow-up (IQR 7 to 11), marked reductions were seen in body weight from 91.0 kg (IQR 75.0 to 106.0) to 82.8 kg (IQR 69.0 to 93.4; P < .0001), in HbA1c from 65 mmol/mol (IQR 54.5 to 85) to 52 mmol/mol (IQR 39 to 62; P < .0001) and in serum triglycerides from 2.80 mmol/L (IQR 1.6 to 3.7) to 1.83 mmol/L (IQR 1.0 to 2.9; P = .0005). Daily insulin requirements fell from 177.5 IU (IQR 101.3 to 213.8) to 58.0 IU (IQR 0 to 112.5; P = .0028).

Conclusion

In patients with partial lipodystrophy, tirzepatide use resulted in substantial statistically significant reductions in weight, glycemic control, serum triglycerides, and daily insulin requirement. We recommend further prospective studies to support these findings and to evaluate its impact earlier in the course of the disorder.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TirzepatideLipodystrophy, Familial PartialHumansFemaleAdultRetrospective StudiesMiddle AgedMaleInsulin ResistanceTreatment Outcome

Stichwörter der Autor:innen

diabetesdual GIP/GLP-1 receptor agonistinsulin resistancepartial lipodystrophytirzepatide

Substanzen

Tirzepatide

Autor:innen und Institutionen

  • University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Cambridge CB2 0QQ, UK.
  • National Severe Insulin Resistance Service, Wolfson Diabetes and Endocrinology Clinic, Cambridge University Hospitals NHS Trust, Cambridge CB2 0QQ, UK.

ORCID-Profile: Mandour O Mandour

Förderung

  • National Institute for Health Research
  • Wellcome Trust
  • NIHR Rare Disease Translational Research Collaboration
  • Cambridge Biomedical Research Centre

Zitieren

APA

Mandour, M. O., Stears, A., Van Der Klaauw, A., Flanagan, C., Gaff, L., Jenkins, C., & Savage, D. B. (2026). Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy. The Journal of Clinical Endocrinology & Metabolism, 111(9), e2146-e2153. https://doi.org/10.1210/clinem/dgag126

Vancouver

Mandour MO, Stears A, Van Der Klaauw A, Flanagan C, Gaff L, Jenkins C, et al. Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy. The Journal of Clinical Endocrinology & Metabolism. 2026;111(9):e2146-e2153. doi:10.1210/clinem/dgag126

BibTeX
@article{Mandour2026,
  author = {Mandour, Mandour O and Stears, Anna and Van Der Klaauw, Agatha and Flanagan, Catherine and Gaff, Lisa and Jenkins, Charlotte and Savage, David B},
  title = {Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  volume = {111},
  number = {9},
  pages = {e2146--e2153},
  doi = {10.1210/clinem/dgag126}
}
Kostenlos starten →